Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies
K Harii, S Arase, R Tsuboi, E Weng, S Daniels, A VanDenburgh, K Harii, S Arase, R Tsuboi, E Weng, S Daniels, A VanDenburgh
Abstract
Background: Bimatoprost 0.03% has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects. The studies described in this report evaluated the efficacy and safety of bimatoprost in Japanese subjects with idiopathic and chemotherapy-induced eyelash hypotrichosis.
Methods: In two multicenter, double-masked, randomized, parallel-group studies (study 1: n=173 [idiopathic]; study 2: n=36 [chemotherapy-induced]), subjects received bimatoprost 0.03% or vehicle applied once daily to the upper eyelid margins. The primary efficacy measure was eyelash prominence measured by Global Eyelash Assessment (GEA) scores. Additional measures were eyelash length, thickness, and darkness, assessed by digital image analysis, and patient satisfaction (Eyelash Satisfaction Questionnaire-9). Safety assessments included adverse-event monitoring and ophthalmic examinations.
Results: Significantly more bimatoprost-treated subjects had at least a one-grade improvement in GEA score from baseline to month 4 compared with vehicle in study 1 (77.3 vs 17.6%; P<0.001) and study 2 (88.9 vs 27.8%; P<0.001). Bimatoprost-treated subjects had significantly greater increases in eyelash length, thickness, and darkness at the primary time point (month 4 in both studies; all P<0.001, study 1; P≤0.04, study 2). The bimatoprost group showed greater subject satisfaction in both studies. The incidence of adverse events was similar in the two groups. Ophthalmic examination showed slightly greater mean reductions in intraocular pressure (IOP) with bimatoprost than with vehicle, and the reductions were within the normal range for daily IOP fluctuations.
Conclusion: Bimatoprost 0.03% was shown to be effective and safe in these studies of Japanese subjects with eyelash hypotrichosis.
Level of evidence i: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Trial registration: ClinicalTrials.gov NCT00907426.
Figures
References
- Draelos ZD. Special considerations in eye cosmetics. Clin Dermatol. 2001;19:424–430. doi: 10.1016/S0738-081X(01)00204-8.
- Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45–52. doi: 10.1517/14740338.6.1.45.
- Shaikh MY, Bodla AA. Hypertrichosis of the eyelashes from prostaglandin analog use: a blessing or a bother to the patient? J Ocul Pharmacol Ther. 2006;22:76–77. doi: 10.1089/jop.2006.22.76.
- Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthetic Plast Surg. 2011;35:116–121. doi: 10.1007/s00266-010-9561-3.
- Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349–358. doi: 10.2147/OPTH.S6480.
- Hunt N, McHale S. Reported experiences of persons with alopecia areata. J Loss Trauma. 2005;10:33–50. doi: 10.1080/15325020490890633.
- Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17:317–328. doi: 10.1002/pon.1245.
- Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004;12:543–549.
- Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, Whitcup SM. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293. doi: 10.1001/archopht.120.10.1286.
- Whitcup SM, Cantor LB, VanDenburgh AM, Chen K. A randomised, double-masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol. 2003;87:57–62. doi: 10.1136/bjo.87.1.57.
- Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol. 2008;92:1387–1392. doi: 10.1136/bjo.2007.128454.
- Brandt JD, VanDenburgh AM, Chen K, Whitcup SM. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023–1031. doi: 10.1016/S0161-6420(01)00584-X.
- Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361–S368. doi: 10.1016/S0039-6257(01)00219-3.
- Woodward DF, Tang ES, Attar M, Wang JW. The biodisposition and hypertrichotic effects of bimatoprost in mouse skin. Exp Dermatol. 2013;22:145–148. doi: 10.1111/exd.12071.
- Smith S, Fagien S, Whitcup SM, Ledon F, Somogyi C, Weng E, Beddingfield FC., III Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66:801–806. doi: 10.1016/j.jaad.2011.06.005.
- Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology. 2010;117:1024–1031. doi: 10.1016/j.ophtha.2009.10.017.
- Woodward JA, Haggerty CJ, Stinnett SS, Williams ZY. Bimatoprost 0.03 % gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol. 2010;9:96–102. doi: 10.1111/j.1473-2165.2010.00487.x.
- Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03 % for eyelash growth. Dermatol Surg. 2010;36:638–649. doi: 10.1111/j.1524-4725.2010.01519.x.
- Na JI, Kwon OS, Kim BJ, Park WS, Oh JK, Kim KH, Cho KH, Eun HC. Ethnic characteristics of eyelashes: a comparative analysis in Asian and Caucasian females. Br J Dermatol. 2006;155:1170–1176. doi: 10.1111/j.1365-2133.2006.07495.x.
- Wirta D, VanDenburgh AM, Weng E, Whitcup SM, Kurstjens S, Beddingfield FC., III Long-term safety evaluation of bimatoprost ophthalmic solution 0.03 %: A pooled analysis of six double-masked, randomized, active-controlled clinical trials. Clin Ophthalmol. 2011;5:759–765. doi: 10.2147/OPTH.S17457.
- Fagien S. Management of hypotrichosis of the eyelashes: focus on bimatoprost. Clin Cosmet Investig Dermatol. 2010;3:39–48. doi: 10.2147/CCID.S5488.
- Martin XD. Normal intraocular pressure in man. Ophthalmologica. 1992;205:57–63. doi: 10.1159/000310313.
- Murgatroyd H, Bembridge J. Intraocular pressure. Cont Educ Anaesth Crit Care Pain. 2008;8:100–103.
- David R, Zangwill L, Briscoe D, Dagan M, Yagev R, Yassur Y. Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br J Ophthalmol. 1992;76:280–283. doi: 10.1136/bjo.76.5.280.
- Fogagnolo P, Orzalesi N, Ferreras A, Rossetti L. The circadian curve of intraocular pressure: can we estimate its characteristics during office hours? Invest Ophthalmol Vis Sci. 2009;50:2209–2215. doi: 10.1167/iovs.08-2889.
Source: PubMed